Compare Five Below Inc (FIVE) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five Below Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Five Below Inc trades at $220.01 (market cap $11.75B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Five Below Inc is the larger of the two by market cap, and Five Below Inc is more actively traded (742,657 versus 1,441,031). Which is the better fit depends on your goals — on Pluang, investors hold Five Below Inc for 46 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| FIVE | SYRE | |
|---|---|---|
Market Cap | $11.75B | $7.52B |
Volume | 742,657 | 1,441,031 |
Sector | Consumer Cyclical | Health |
52-Week High | $262.72 | $108.92 |
52-Week Low | $147.05 | $22.18 |
Typical Hold Time | 46 Days | 0 Days |
Enterprise Value | $12.60B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five Below (FIVE) trades at $213.35, down slightly by 0.11% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $1.68 beating expectations of $1.40. Revenue growth remains robust, projected to reach $5.3B in 2026, while profitability metrics show a net income margin of 11.65% and ROE of 28.25%. Recent news highlights the company's focus on digital marketing, store revamps, and a $600 million buyback program to drive future growth.
The outlook for FIVE remains positive with strong analyst support (60% buy ratings) and a consensus price target of $298.44, representing significant upside potential. However, investors should monitor execution risks associated with premium valuation multiples (P/E 19.14, P/S 2.23) and potential consumer spending headwinds. The stock's current bearish technical picture contrasts with strong fundamentals, creating potential entry opportunities for long-term investors.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
